Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB407 in adults with cystic fibrosis
NCT05504837Phase 1Recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of KB407 in cystic fibrosis (CF) (4 cohorts), sponsored by Krystal Biotech, Inc. Primary endpoint: Safety and tolerability based upon assessment of adverse events, physical examinations, vital signs, ECG, and clinical laboratory test results at 6 months. Started Jun 2023; status: recruiting.
02
Drugs
KB407
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05504837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504837.